SynthesisInternational journal of geriatric psychiatry2018
Efficacy and tolerability of antidepressants in Parkinson's disease: A systematic review and network meta-analysis.
Synthesis in International journal of geriatric psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 4 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Psychiatric Association of Türkiye Mood Disorders Section Depression Treatment Guideline - III: Treatment Approach for Depression Subtypes and Special Groups, Psychotherapies, and Psychosocial Interventions.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2026Guideline
- Management of Anxiety in Parkinson's Disease.Movement disorders clinical practice · 2025Pooled it
- Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Parkinson's Disease: A Systematic Review and Meta-Analysis.Clinical drug investigation · 2024Pooled it
- Comparative Efficacy and Safety of Dopamine Agonists in Advanced Parkinson's Disease With Motor Fluctuations: A Systematic Review and Network Meta-Analysis of Double-Blind Randomized Controlled Trials.Frontiers in neuroscience · 2021Pooled it
- Perspective: Depression in Persons with Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026Review
- Potential Effects of Music on Non-Motor Symptoms in Parkinson's Disease: Translating Mechanisms to Therapy.Neurology international · 2026Review
- Diagnosis and Management of Parkinson Disease in Individuals with Pre-Existing Mood Disorders.International journal of environmental research and public health · 2026Review
- Review
- Depressive symptoms can negatively influence patient reported disease severity after subthalamic nucleus stimulation for Parkinson's disease.Journal of Parkinson's disease · 2025Article
- Approaches for treating neuropsychiatric symptoms in Parkinson's disease: a narrative review.Therapeutic advances in neurological disorders · 2025Review
- Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2023Article
- Exploring depression in Parkinson's disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- Pharmacological and Non-Pharmacological Treatments for Depression in Parkinson's Disease: An Updated Review.Medicina (Kaunas, Lithuania) · 2023Review
- Depression in Major Neurodegenerative Diseases and Strokes: A Critical Review of Similarities and Differences among Neurological Disorders.Brain sciences · 2023Review
- Recent hospitalization and risk of antidepressant initiation in people with Parkinson's disease.BMC geriatrics · 2022Article
- Towards an understanding of the pathological basis of senile depression and incident dementia: Implications for treatment.Psychiatry and clinical neurosciences · 2022Review
- Parkinson and depression: review and outlook.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- Clinical uses of Bupropion in patients with Parkinson's disease and comorbid depressive or neuropsychiatric symptoms: a scoping review.BMC neurology · 2022Article
- Comparison of pramipexole and citalopram in the treatment of depression in Parkinson's disease: A randomized parallel-group trial.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2022Article
- The neuropsychiatry of Parkinson's disease: advances and challenges.The Lancet. Neurology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo systematically review and analyze the efficacy and tolerability of different antidepressant pharmacologic treatments for depressive symptoms in Parkinson's disease (PD)
methodsWe searched PubMed, EMBASE, Cochrane database (CENTRAL), clinicaltrials.gov, and bibliographies for randomized controlled trials investigating the efficacy of antidepressant medications versus a non-treatment, placebo, or active treatment groups for depressive symptoms in PD. Twenty of 3191 retrieved studies (1893 patients) were included, but not all could be meta-analyzed. We used a random-effects model meta-analysis to compare depression scores between an active drug and placebo or control group then used a network meta-analysis to compare the effectiveness of different antidepressant classes. The primary outcome was the efficacy of different classes of antidepressant medications in PD patients with depressive symptoms, measured by standardized mean difference (SMD) in depression score from baseline compared with control.
resultsPairwise meta-analysis suggested that type B-selective monoamine oxidase inhibitors (SMD = -1.28, CI = -1.68, -0.88), selective serotonin reuptake inhibitors (SMD = -0.49, CI = -0.93, -0.05), and tricyclics (SMD = -0.83, CI = -1.53, -0.13) are effective antidepressants in PD. Network meta-analysis showed that monoamine oxidase inhibitors had the largest effect on depression in PD (SMD (vs selective serotonin reuptake inhibitors) = -0.78, CI = -1.55, -0.01), but these might not be considered traditional antidepressants given their type B selectivity.
conclusionsAlthough limited by few data, this review suggests that multiple antidepressant classes are potentially efficacious in the treatment of depression in PD, but that further comparative efficacy and tolerability research is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.